The proposed acquisition builds on Regeneron’s existing partnership with Decibel and will advance key gene therapy programs for hearing loss.   Under the terms of the proposed deal, Regeneron will pay $109 million to Decibel upon closing, and up to $213 million if specific milestones are met. The pair first teamed up in 2017 to find and develop gene therapies for hearing loss. In November 2021, they extended their collaboration and added two additional gene therapy programs targeting various forms…